Therefore, the U.S. Food and Drug Administration (FDA) has accelerated the approval of pembrolizumab combined with trastuzumab and chemotherapy for the first-line treatment of HER-2-positive advanced gastric cancer, and the regimen is also included in the NCCN guidelines version 2.2022 for gastric cancer (10). This evidence concerns the gene ERBB2 and gastric cancer.